Drug
Lorigerlimab
Lorigerlimab: highest development phase Phase 2, developed by MacroGenics. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lorigerlimab NCT05475171 | Phase 2 | Metastatic Cancer |
| Lorigerlimab NCT07565155 | Phase 2 | Pancreatic Adenocarcinoma |
| lorigerlimab NCT05848011 | Phase 2 | Androgen-Independent Prostatic Cancer |
| Lorigerlimab NCT06730347 | Phase 2 | Platinum-resistant Ovarian Cancer |
| Lorigerlimab NCT03761017 | Phase 1 | Squamous Cell Non Small Cell Lung Cancer |
Latest
No recent events.
Follow Lorigerlimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.